Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
Empa 25mg is indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. It may also be used to reduce the risk of cardiovascular death in patients with established heart disease.
Pharmacology:
Empagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. It works by reducing glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and decreased blood glucose levels.
Dosage:
The recommended dose is 25 mg once daily, taken orally in the morning. Dosage may vary based on patient response and tolerability.
Administration:
Should be taken with or without food. Swallow the tablet whole with water.
Interaction:
May interact with diuretics, insulin, or insulin secretagogues (e.g., sulfonylureas), increasing the risk of hypoglycemia. Monitor closely if used with antihypertensive agents or drugs that affect renal function.
Contraindications:
Contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment (eGFR <30 mL/min/1.73m²), or hypersensitivity to empagliflozin.
Side Effects:
Common side effects include urinary tract infections, increased urination, thirst, and low blood sugar (especially with insulin). Rare but serious side effects include ketoacidosis and genital mycotic infections.
Pregnancy & Lactation:
Not recommended during pregnancy or breastfeeding. Use only if the potential benefit justifies the potential risk to the fetus or infant.
Precautions & Warnings:
Use with caution in elderly patients, those with renal impairment, or those at risk for volume depletion. Monitor renal function regularly.
Therapeutic Class:
Sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Storage Conditions:
Store below 30°C, in a cool and dry place. Protect from light and moisture. Keep out of reach of children.
Change Language